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approved by the institutional review board, and written informed 
consent was obtained from each subject before the study.
Results: Plasma concentration of MNA, renal creatinine clearance, 
and CLTS,MNA were 9.9 (8.1) ng/mL, 139 mL/min/1.66 m2, and 
181 (110) mL/min/1.66 m2, respectively, indicating that the tubular 
secretion of MNA is involved in its renal clearance. Eight SNPs, 
–151C> A, –66T> C, 191G> A, 373C> T, 708C> T, 1490G> C, IVS5–
12G> C, and IVS5–4G> A, were detected on SLC47A1 gene with 
minor allele frequencies of 0.009, 0.194, 0.009, 0.009, 0.083, 0.009, 
0.343, and 0.463, respectively. A loss-of-function allele of SLC22A2, 
808G> T, was detected with minor allele frequency of 0.105 and 1 
subject was found having this variant as homozygote. She showed 
almost null CLTS,MNA; therefore, this subject was excluded from the 
analysis. Seventeen subjects having either –66C/C or T/C alleles 
showed a trend toward reduced CLTS,MNA compared with those hav-
ing the wild-type genotype (151 [IQR, 107–167] vs 184 [115–227] 
mL/min/1.66 m2; P = 0.08). Other variants showed no appreciable 
effects on CLTS,MNA.
Conclusion: We consider that CLTS,MNA may be a useful biomarker 
of the activity of renal organic cation transporters. The –66C allele 
of hMATE1/SLC47A1 may contribute to reduced renal clearance of 
MNA in healthy subjects not having homozygous 808G> T variant 
of hOCT2/SLC22A2.
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Introduction: More than 80 allelic variants have been described for 
CYP2D6 that result in poor (PM), efficient or extensive (EM) and 
ultrarapid (UM) metabolizers of CYP2D6 drug substrates. The dis-
tribution of PMs, Ems, and UMs varies markedly among human 
populations; however, it has been particularly difficult to determine in 
countries with wide ethnic diversity. Currently, the Mexican popula-
tion is composed of Mestizos (≈90%) and > 85 different ethno lin-
guistic indigenous populations (Mexican-Amerindians). Lacandones 
and Tzeltales are Mexican indigenous individuals that inhabit the 
state of Chiapas.
Aim: To perform a genetic analysis of CYP2D6 to determine the 
frequency of the hypothetical PM and UM status in Lacandones, 
Tzeltales, and 2 mestizo populations and compare it with previously 
reported Mexican populations.
Patients (or Materials) and Methods: The CYP2D6 genotype was 
analyzed in 154 Mexican Lacandones (ML), 26 Tzeltales (MT), 
249 Mexican Mestizos from Central Mexico (MM1), and 100 
Mexican Mestizos from Chiapas (MM2) healthy volunteers. All 
participants gave informed consent before its participation. The 
study was approved by the local ethical committee. Genomic DNA 
was extracted from blood samples by standard techniques. CYP2D6 
genotyping was performed by PCR for CYP2D6*5 and multiplica-
tion alleles, TaqMan® assays (AB) were used for CYP2D6*2,*3, *4, 
*6, *10, *17, *35, *41 and copy number variations. Differences in 
CYP2D6 allele frequencies were compared by using the chi-square 
(χ 2) test and/or Fisher’s exact test. Statistical analysis was done by 
STATISTICA 4.3 and GraphPad Prism 3.02 softwares.
Results: The PM frequency was very low in MM1 (0.8%) and 
MM2 (1%), while it was absent from MLs and MTs in a manner 
similar to 0% previously found in Tepehuanos and in other Mexican 
Amerindian populations. The UM phenotype frequency in MLs was 
also very similar to Tepehuanos (1.3% and 1.5%, respectively) and 
to Mexican American populations previously studied. In MTs the 
UM frequency was 0%, while MM1 and MM2 showed a 5.6% and 
3.0 frequency, respectively.
Conclusion: These data indicate that the frequencies of CYP2D6 PM 
and UM predicted phenotypes are very similar between Tepehuanos, 
Lacandones, and Tzeltales, but differ from Mexican Mestizos from 
Central and Southeastern Mexico. The predicted PM phenotype was 
very similar between MM from Central and Southeastern Mexico 
but varied in the frequency of UM. These findings reveal Mexican 
populations diversity that could have important implications in drug 
response to CYP2D6 substrates.
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Introduction: Epilepsy is the most prevalent chronic neurologic dis-
order that affects 65 million people worldwide. Phenytoin (PHT) is 
1 of the most widely prescribed antiepileptic drugs (AEDs); however, 
large interindividual variability in doses and concentrations has been 
observed in epilepsy treatment with PHT. Functional polymorphisms 
in genes encoding drug-metabolizing enzymes, drug transporters, 
and drug targets have been suggested to contribute to this genetic 
variability.
Aim: To evaluate the association of CYP2C9, CYP2C19, ABCB1, 
and ABCC2 polymorphism on PHT plasma levels in epileptic 
patients.
Patients (or Materials) and Methods: The present investigation was 
carried out in 57 consecutive patients (16–65 years) suffering epilepsy 
and treated with phenytoin. Approval from the institutional biomedi-
cal research ethics committee and the informed consent of patients 
was obtained before enrollment into the study. Genomic DNA was 
isolated from blood samples by standard technique. Genotyping 
of CYP2C9*2, CYP2C19*2 and *3, ABCB1 C1234T, C3435T, 
G2677A/T, ABCC2 G24A, and G1249A was performed by real-time 
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PCR using allele-specific probes, and CYP2C9*3 by PCR-RFLP. PHT 
plasma levels were determined by radioimmunoassay.
Results: Twenty-six patients showed PHT therapeutic levels (10–20 
µg/mL), 24 subtherapeutic and 7 supratherapeutic. Three cases, 
2 CYP2C9 *1/*2, and 1 CYP2C19*1/3, had subtherapeutic levels. 
Patients with wild-type ABCB1 and ABCC2 genotypes exhibited a 
tendency to have increased PHT plasma levels than patients with 
mutant genotypes.
Conclusion: PHT plasma levels showed great variability among 
patients that was not statistically significant correlated to the genetic 
polymorphisms analyzed, although ABCB1 and ABCC2 wild-type 
genotypes showed a trend toward higher levels. Further investigations 
are needed with other candidate genes and a larger sample.
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Introduction: Aspirin is an antiplatelet agent commonly used in 
treatment of patients with high risk to develop stroke and myocar-
dial infarction. However, interindividual variability regarding the 
inhibition of platelet function by aspirin is well documented. In this 
study, the correlation between platelet glycoproteins (GPIa C807T 
and GPIba C-5T) and cyclooxygenase 2 (COX-2 G-765C) poly-
morphisms and antiplatelet response in patients treated with aspirin 
was investigated.
Patients (or Materials) and Methods: Jordanian adult patients 
(n = 584) who are taking aspirin as an antiplatelet agent partici-
pated in the study. Platelet aggregation response was measured using 
Multiplate Analyzer® system. Polymerase chain reaction–restriction 
fragment length polymorphism assay (PCR-RFLP) was used for geno-
typing of the examined polymorphisms.
Results: Aspirin resistance was found in 15.8% of patients. Response 
to aspirin was significantly associated with GPIba C-5T polymor-
phism (P < 0.05). However, the GPIa C807T and COX-2 G-765C 
polymorphisms were not related to aspirin resistance (P > 0.05).
Conclusion: A considerable fraction of the Jordanian population is 
resistant to the antiplatelet effect of aspirin, which might be related 
to GPIba C-5T polymorphism.
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Introduction: Pharmacogenomics is intervening in cardiovascular 
therapeutic armamentarium to tailor therapy to individual’s genetic 
makeup. Accordingly, the potential implication of PlA gene variants 
of GPIIIa of platelet GP IIb/IIIa as a genetic risk factor provocateur 
and/or a therapeutic outcome modulator to antiplatelet therapy in 
ACS was probed.
Patients (or Materials) and Methods: Study enrolled 22 controls 
and 44 ACS patients (NSTEMI vs STEMI). They were risk strati-
fied (TIMI score), sampled for genotyping and estimation of plate-
let aggregation and oxidative indices, then subdivided according to 
add-on antiplatelet therapy into: clopidogrel or tirofiban subgroups. 
After 48 hours, the therapeutic outcome was assessed; clinically [pain 
relief or complication prevalence (symptomatic, electrocardiographic, 
or hemorrhagic) and the investigational estimates were re-assessed. 
Intraprocedural evaluation of chest pain, ECG tracing, and angio-
graphic findings (thrombus extent, TIMI flow, myocardial blush) 
were reported in patients who underwent percutaneous intervention 
[PCI].
Results: Frequency of PlA2 vs PlA1 allele was higher in ACS patients 
(significant in < 60 years /doubled in STEMI vs NSTEMI). TIMI 
score, stratification permitted considering PlA2 variant as inde-
pendent risk factor in UA/NSTEMI subsets. This was fostered by 
intraprocedural finding of more stenotic and thrombotic lesions in 
PlA2 carriers. A lack of significant association between PlA variants 
and changes in platelet aggregation or oxidative indices, debate their 
causal relation to PlA2 variant being an ACS risk factor. A positive 
correlation was observed between PlA variants and the therapeutic 
response outcome to both clopidogrel and tirofiban regarding platelet 
aggregation and relief of chest pain while their antioxidative poten-
tiality was negatively correlated only to PlA1 carriers.
Conclusion: PlA2 variant could be considered a genetic risk factor 
contributor rather than an antiplatelet therapeutic response modula-
tor when speaking of ACS. This awaits larger scale pharmacogenomic 
studies before a final statement is declared so as to individualize anti-
platelet therapy to the best of its therapeutic outcome in ACS settings.
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Introduction: Ultrarapid drug metabolism (UM) mediated by 
CYP2D6 is associated with duplicated or amplified functional 
CYP2D6 alleles. However, duplicated CYP2D6 alleles only explains 
a fraction (10%–30%) of the UM phenotype observed in Caucasian 
populations, and other biochemical and/or genetic factors involved 
in UM phenotype remain unexplained yet. CYP2D6 -1584C> G has 
been related with changes in CYP2D6 expression, being -1584G 
associated with higher expression. The aim of this study was to 
explore the relationship between CYP2D6 -1584C> G polymorphism 
and the debrisoquine hydroxylation capacity.
